Type Condition

Cullman, AL

205 Clinical Trials near Cullman, AL

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Endoscopic Airway Examination for Predicting Intubation Complications

Birmingham, Alabama
Purpose of study: To contrast and compare the Mallampatti test to a comprehensive airway grading test using a rigid 75-degree angle laryngoscope (CPAG) Study Hypothesis: The investigators hypothesize that the CPAG will have greater sensitivity and specificity for predicting difficulty laryngoscopy as compared to the Mallampati test. The investigators plan to test this hypothesis by comparing the correlation of (a) airway Mallampati airway grading (predicted airway difficulty) versus (b) CPAG view grading and Cormack Laryngoscopy assessment (observed airway difficulty).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

Defibrillator Lead for Rapid Heartbeat

Huntsville, Alabama
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12+

998 Participants Needed

AGN1 LOEP SV Kit for VCFs

Birmingham, Alabama
This trial is testing a new device called the AGN1 LOEP SV Kit for patients with painful spinal fractures. The device works by stabilizing the broken bone in the spine to reduce pain.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 85

408 Participants Needed

Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation

Huntsville, Alabama
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2650 Participants Needed

VNS for Bipolar Depression

Huntsville, Alabama
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

Biofeedback + Injection for Bowel Incontinence

Birmingham, Alabama
This trial is for patients with severe fecal incontinence who haven't responded to initial treatments. It compares two methods: muscle training and a treatment that adds bulk to the rectum. The goal is to see which method better reduces incontinence episodes.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

275 Participants Needed

WiSE CRT System for Heart Failure

Huntsville, Alabama
This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

300 Participants Needed

Carotid Stenting vs. Endarterectomy for Carotid Stenosis

Huntsville, Alabama
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:35 - 100

2486 Participants Needed

Symphony Thrombectomy for Pulmonary Embolism

Huntsville, Alabama
Evaluation of the Safety and Efficacy of the Symphony Thrombectomy System in the Treatment of Pulmonary Embolism
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

109 Participants Needed

Intervention Programs for Childhood Behavior

Huntsville, Alabama
The primary purpose of this project is to test a comprehensive, two-part intervention with ReACT and a recently adapted, Coping Power+ Program. ReACT and PBIS are school-wide universal interventions. Coping Power and Coping Power+ are targeted preventive interventions designed to assist at-risk 7th grade students to improve their coping with interpersonal stressors during middle school. This project will evaluate the effects of the program on teacher, student and parent perceptions of school climate, student behavior, social-emotional competence, disciplinary infractions, and identity for 7th grade students in Coping Power or Coping Power+
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:10 - 14

1093 Participants Needed

TAVR for Aortic Stenosis

Huntsville, Alabama
This trial tests advanced heart valves that can be inserted without open-heart surgery in patients with a narrowed and stiff aortic valve due to calcium buildup. The new valve is placed through a small cut and guided to the heart, where it replaces the damaged valve. This minimally invasive procedure has recently become the only lifesaving solution for patients who cannot tolerate standard surgical valve replacement.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

2250 Participants Needed

PCI vs Medical Management for Aortic Stenosis

Huntsville, Alabama
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

4000 Participants Needed

ChEVAS for Abdominal Aortic Aneurysm

Huntsville, Alabama
Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

13 Participants Needed

Neuroguard IEP System for Carotid Artery Stenosis

Huntsville, Alabama
This trial is testing a new device called the Neuroguard IEP System for people with significant narrowing of the carotid arteries. The device opens up the blocked artery, catches any loose particles, and keeps the artery open with a small tube. This group is targeted because they are at high risk for complications from traditional surgery.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:20 - 80

305 Participants Needed

SAPIEN M3 System for Mitral Valve Regurgitation

Huntsville, Alabama
This trial will test the safety and effectiveness of the SAPIEN M3 System in patients with severe mitral regurgitation who can't use other treatments. The device helps the heart valve close properly to stop it from leaking. The SAPIEN transcatheter heart valve (THV) has been previously tested and shown to be safe and effective in the pulmonary position.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

900 Participants Needed

SyncAV CRT Programming for Heart Failure

Huntsville, Alabama
This trial is testing a special setting in heart devices called SyncAV ON to help patients with new heart devices. It aims to improve how well their hearts pump blood by adjusting the timing of electrical signals in the heart.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

1686 Participants Needed

Cordella™ Sensor System for Heart Failure

Birmingham, Alabama
This trial is testing a device called the Cordella PA Sensor System, which monitors heart pressure. It is aimed at patients with moderate to severe heart failure who need better treatment options. The device helps doctors track heart function and adjust treatments accordingly. The Cordella PA Sensor System is a novel device for continuous monitoring of heart pressure, similar to the previously approved CardioMEMS device.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

738 Participants Needed

AMPLATZER PFO Occluder for Patent Foramen Ovale

Huntsville, Alabama
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 60

1214 Participants Needed

Nellix System for Abdominal Aortic Aneurysm

Huntsville, Alabama
Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

98 Participants Needed

WATCHMAN Device for Stroke Prevention in Atrial Fibrillation

Huntsville, Alabama
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

481 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

Renal Denervation for High Blood Pressure

Huntsville, Alabama
The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:20 - 80

337 Participants Needed

Stent Graft Systems for Abdominal Aortic Aneurysm

Huntsville, Alabama
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

450 Participants Needed

Botanical Extracts + Melatonin for Sleep

Huntsville, Alabama
The purpose of this study is to evaluate the efficacy and superiority of a botanical based sleep product on sleep quality as compared to melatonin, among healthy female participants.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:35 - 55
Sex:Female

88 Participants Needed

Implantable Defibrillator for Heart Attack

Huntsville, Alabama
This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

700 Participants Needed

Aticaprant for Depression

Huntsville, Alabama
This trial is testing if aticaprant can help adults with major depressive disorder who haven't responded well to current antidepressants. The medication works by targeting brain chemicals to improve mood and pleasure.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 64

350 Participants Needed

NMRA 335140 for Depression

Huntsville, Alabama
This trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 65

332 Participants Needed

BNT162b2 Vaccine for COVID-19

Huntsville, Alabama
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, * in people who are 12 years of age and older, * who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). * The study is about 6 months long for each participant. * Participants will have at least 5 visits to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken. Substudy B: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, * in people who are 12 years of age and older, * who are COVID-19 vaccine-naïve * who have had any positive SARS-CoV-2 test result \>28 days before study vaccine administration. * The study is about 6 months long for each participant. * Participants will have at least 5 visits to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken. Substudy C: * This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to: * Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and, * Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and, * Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2). * Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1). * The study is about 6 months long for each participant. * Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic. * At each clinic visit a blood sample will be taken. * At least 1 nasal swab will taken.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:12+

1000 Participants Needed

Vericiguat for Heart Failure

Huntsville, Alabama
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

6105 Participants Needed

Upadacitinib for Giant Cell Arteritis

Huntsville, Alabama
This trial tests if upadacitinib, combined with reducing steroid doses, helps people with giant cell arteritis achieve and maintain remission by reducing inflammation. Upadacitinib has been approved for the treatment of rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis, and is under investigation for other conditions.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50+

429 Participants Needed

Chemotherapy + Bevacizumab for Non-Small Cell Lung Cancer

Huntsville, Alabama
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

1501 Participants Needed

1...567

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Cullman, AL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Cullman, AL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Cullman, AL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Cullman, AL is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Cullman, AL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Cullman, AL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Cullman, AL?

Most recently, we added Nerandomilast for Interstitial Lung Disease, Vicadrostat + Empagliflozin for Chronic Kidney Disease and Oral Tranexamic Acid for Shoulder Replacement Surgery to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards in Cullman, AL?

The clinics in Cullman, AL currently recognized as SuperSites are: University of Alabama at Birmingham in Birmingham, Alabama

Popular Searches

By Condition

Depression Clinical Trials in Alabama

Anxiety Clinical Trials in Alabama

Schizophrenia Clinical Trials in Alabama

ADHD Clinical Trials in Alabama

Bipolar Disorder Clinical Trials in Alabama

Multiple Sclerosis Clinical Trials in Alabama

Autism Clinical Trials in Alabama

Treatment Resistant Depression Clinical Trials in Alabama

Borderline Personality Disorder Clinical Trials in Alabama

Social Anxiety Disorder Clinical Trials in Alabama

Parkinson's Disease Clinical Trials in Alabama

Alzheimer's Disease Clinical Trials in Alabama

By Location

Clinical Trials near Birmingham, AL

Clinical Trials near Mobile, AL

Clinical Trials near Huntsville, AL

Clinical Trials near Anniston, AL

Clinical Trials near Dothan, AL

Clinical Trials near Montgomery, AL

Clinical Trials near Tuscaloosa, AL

Clinical Trials near Homewood, AL

Clinical Trials near Cullman, AL

Clinical Trials near Muscle Shoals, AL

Clinical Trials near Jasper, AL

Clinical Trials near Sheffield, AL

Other People Viewed

By Subject

197 Clinical Trials near Decatur, AL

34 Eczema Trials near Birmingham, AL

28 Depression Trials near Birmingham, AL

Top Clinical Trials near Jasper, AL

Top Clinical Trials near Hueytown, AL

Top Clinical Trials near Haleyville, AL

Top Clinical Trials near Foley, AL

Top Clinical Trials near Florence, AL

Top Clinical Trials near Daphne, AL

Top Clinical Trials near Athens, AL

Top Clinical Trials near Andalusia, AL

Top Clinical Trials near Gulf Shores, AL

By Trial

fMRI-Neurofeedback for PTSD

DASH Diet for Gut Health

Electrical Stimulation for Paralysis/Paresis

Sound Stimulation for Auditory Processing

B-POC Training for Physical Fitness

Non-silicone Gel Sheet for Burn Scars

Broccoli Sprouts for Ulcerative Colitis

Emergency Maternity Housing for Pregnant Mothers in Need

DFMO + Etoposide for Neuroblastoma

Fenofibrate for Klinefelter Syndrome

Doctor Communication Intervention for Patient Safety in Pacemaker/ICD Procedures

Talquetamab Combination Therapy for Multiple Myeloma

Related Searches

Top Clinical Trials near Cumberland, MD

Top Clinical Trials near Cypress, TX

Top Clinical Trials near Dalton, GA

Ketogenic Diet for NASH Cirrhosis Weight Loss

Glucarpidase for Central Nervous System Lymphoma

ABBV-514 + Budigalimab for Lung & Head and Neck Cancers

Upadacitinib vs Adalimumab for Rheumatoid Arthritis

Testosterone Nasal Gel for Spinal Cord Injury

Couplet Care Bassinet for Mother and Infant Outcomes

Senza5 CART5 for T-Cell Lymphoma

Red Light Therapy for Artificial Light Exposure

Bupivacaine for Endometriosis

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial